oncology

The healthcare sector will be on watch Wednesday with a highly anticipated earnings report from Johnson & Johnson (NYSE:JNJ) before market open. Earnings Estimates: Analysts expect Johnson & Johnson to report fourth quarter revenue of $22.44 billion according to data from Benzinga Pro. The...

BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine. On Wednesday, BioNTech reported a revenue and earnings drop as it continues its shift towards cancer drug...

On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net quarterly loss due to...

In a recent report, Bank of America identified the “Disruptive Dozen” emerging technologies that have the most potential to disrupt and revolutionize the healthcare sector over the next years. New therapy for ALS (amyotrophic lateral sclerosis) and a blood test for Alzheimer’s...

SVB Securities, a division of SVB Financial Group (NASDAQ: SIVB), believes BioNTech SE – ADR (NASDAQ: BNTX) stock is trading below the most negative scenario for the COVID-19 vaccine market. The SVB Financial Analyst: Daina M. Graybosch upgraded the stock from Market Perform to...

Cannabotech has announced a new strategic partnership with the Californian corporation go NXT LVL. This agreement will allow Cannabotech's integrative oncology products to be developed and manufactured at go NXT LVL's facilities in accordance with the California Medical Cannabis Regulations...

Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to become a best-in-class P53 stabilizer, the Company said, noting that more than 50% of tumors harbor wild-type p53....

CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc's (NASDAQ: NTRA) Signatera molecular residual disease (MRD) test.  An accompanying Billing and Coding...

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) spun out a new company, Radionetics, focused solely on a burgeoning field of radiopharmaceuticals. Radiopharmaceuticals are a class of drugs that contain radioactive isotopes. Those radioisotopes are carried by the treatments to receptors...

Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a total upfront cash payment to Takeda of $10 million and $35 million in Calithera Series...

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference. XMT-2056 is an Immunosynthen STING-agonist ADC candidate, targeting an epitope of human epidermal growth factor...

TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.  Related: TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development. The preclinical...

AbCellera Biologics Inc (NASDAQ: ABCL) and Everest Medicines Limited have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.  The partnership will help expand Everest's...

The FDA has signed off Oric Pharmaceuticals Inc's (NASDAQ: ORIC) Investigational New Drug Application (IND) for ORIC-533. The Company can now proceed into a first-in-human clinical trial in which ORIC-533 will be tested as a single agent in an undisclosed tumor type not...

Silverback Therapeutics Inc (NASDAQ: SBTX) stock dropped to the lowest level since its IPO in December 2020 in reaction to interim data from SBT6050 Phase 1/1b trial for solid tumors. The trial in advanced or metastatic HER2-expressing or amplified solid cancer was designed to...